Skip to main content
. 2014 Jul 30;2014(7):CD003488. doi: 10.1002/14651858.CD003488.pub3
Methods Study design: randomized controlled trial
Study dates: 1969 to 1971
Diagnostics: clinical diagnosis and serological or virological. Haemagglutination inhibition (HI) test performed on paired sera; positive result was a fourfold rise in titre or a fixed level at 1:640 or more.
Participants Number of participants: randomized: 26 enrolled (7 in corticosteroid group; 19 in control group)
Age: 6.6 to 9.5 years
Inclusion criteria: children diagnosed with dengue shock syndrome using serological confirmation
Exclusions: not specified
Interventions 1. Hydrocortisone hemisuccinate: intravenous 25 mg/kg/day; 5 mg/kg at start, rest given in divided doses every four to six hours in addition to fluid replacement
2. No medication (fluid replacement only)
Outcomes 1. Death
2. Duration of shock
3. Number requiring fluid replacement
4. Number needing blood transfusion
Notes Location: Ramathibodi Hospital, Bangkok, Thailand
Transmission: not specified
Funding: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Quote: "A card was drawn at onset of shock to decide which treatment program would be given", no more detail about sequence generation
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel (performance bias) All outcomes Unclear risk Not specified
Blinding of outcome assessment (detection bias) All outcomes Unclear risk Not specified
Incomplete outcome data (attrition bias) All outcomes Low risk No losses to follow‐up were reported
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified